Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study

Imagem de Miniatura
Arquivos
art_FITZMAURICE_Global_Regional_and_National_Cancer_Incidence_Mortality_Years_2017.PDF (12.34 MB)
Citações na Scopus
3131
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER MEDICAL ASSOC
Autores
FITZMAURICE, Christina
COLLABORATION, Global Bourden Disease Cancer
ALLEN, Christine
BARBER, Ryan M.
BARREGARD, Lars
BHUTTA, Zulfiqar A.
BRENNER, Hermann
DICKER, Daniel J.
CHIMED-ORCHIR, Odgerel
DANDONA, Rakhi
Citação
JAMA ONCOLOGY, v.3, n.4, p.524-548, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
IMPORTANCE Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. OBJECTIVE To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. EVIDENCE REVIEW Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data. Cancer incidence was calculated by dividing mortality estimates through the modeled MI ratios. To calculate cancer prevalence, MI ratios were used to model survival. To calculate YLDs, prevalence estimates were multiplied by disability weights. The YLLs were estimated by multiplying age-specific cancer deaths by the reference life expectancy. DALYs were estimated as the sum of YLDs and YLLs. A sociodemographic index (SDI) was created for each location based on income per capita, educational attainment, and fertility. Countries were categorized by SDI quintiles to summarize results. FINDINGS In 2015, there were 17.5 million cancer cases worldwide and 8.7 million deaths. Between 2005 and 2015, cancer cases increased by 33%, with population aging contributing 16%, population growth 13%, and changes in age-specific rates contributing 4%. For men, the most common cancer globallywas prostate cancer (1.6 million cases). Tracheal, bronchus, and lung cancerwas the leading cause of cancer deaths and DALYs in men (1.2 million deaths and 25.9 million DALYs). For women, the most common cancerwas breast cancer (2.4 million cases). Breast cancerwas also the leading cause of cancer deaths and DALYs forwomen (523000 deaths and 15.1 million DALYs). Overall, cancer caused 208.3 million DALYs worldwide in 2015 for both sexes combined. Between 2005 and 2015, age-standardized incidence rates for all cancers combined increased in 174 of 195 countries or territories. Age-standardized death rates (ASDRs) for all cancers combined decreased within that timeframe in 140 of 195 countries or territories. Countries with an increase in the ASDR due to all cancers were largely located on the African continent. Of all cancers, deaths between 2005 and 2015 decreased significantly for Hodgkin lymphoma (-6.1%[95% uncertainty interval (UI), -10.6% to -1.3%]). The number of deaths also decreased for esophageal cancer, stomach cancer, and chronic myeloid leukemia, although these results were not statistically significant. CONCLUSION AND RELEVANCE As part of the epidemiological transition, cancer incidence is expected to increase in the future, further straining limited health care resources. Appropriate allocation of resources for cancer prevention, early diagnosis, and curative and palliative care requires detailed knowledge of the local burden of cancer. The GBD 2015 study results demonstrate that progress is possible in the war against cancer. However, the major findings also highlight an unmet need for cancer prevention efforts, including tobacco control, vaccination, and the promotion of physical activity and a healthy diet.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/21236
Referências
  1. Action CC, 2015, M REP LOND NOV 3 4
  2. Ahern RM, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-8
  3. Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
  4. Anderson BO, 2011, LANCET ONCOL, V12, P387, DOI 10.1016/S1470-2045(11)70031-6
  5. Anderson BO, 2015, CANC DIS CONTROL PRI, V3
  6. Arbyn M, 2009, EUR J CANCER, V45, P2640, DOI 10.1016/j.ejca.2009.07.018
  7. Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124
  8. Bray F, 2016, CANCER EPIDEM BIOMAR, V25, P3, DOI 10.1158/1055-9965.EPI-15-1109
  9. Cao Y, 2016, JAMA ONCOL, V2, P762, DOI 10.1001/jamaoncol.2015.6396
  10. Carlson JW, 2010, AM J SURG PATHOL, V34, P118, DOI 10.1097/PAS.0b013e3181c17fe6
  11. Chalkidou K, 2014, LANCET ONCOL, V15, pE119, DOI 10.1016/S1470-2045(13)70547-3
  12. Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
  13. Chang ET, 2006, CANCER EPIDEM BIOMAR, V15, P1765, DOI 10.1158/1055-9965.EPI-06-0353
  14. Choi KS, 2015, BRIT J CANCER, V112, P608, DOI 10.1038/bjc.2014.608
  15. Clague J, 2012, CURR ONCOL REP, V14, P550, DOI 10.1007/s11912-012-0265-5
  16. Clark H, 2013, LANCET, V381, P510, DOI 10.1016/S0140-6736(13)60058-6
  17. Colditz GA, 2014, CA-CANCER J CLIN, V64, P186, DOI 10.3322/caac.21225
  18. Coleman MP, 2014, LANCET, V383, P564, DOI 10.1016/S0140-6736(13)62225-4
  19. de Martel C, 2013, GASTROENTEROL CLIN N, V42, P219, DOI 10.1016/j.gtc.2013.01.003
  20. Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
  21. Flaxman AD, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-35
  22. Ford AC, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3174
  23. Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1
  24. Forouzanfar MH, 2016, LANCET, V388, P1659
  25. Gandini S, 2005, EUR J CANCER, V41, P2040, DOI 10.1016/j.ejca.2005.03.034
  26. Gelband H, 2016, LANCET, V387, P2133, DOI 10.1016/S0140-6736(15)00755-2
  27. Grady D., 2016, NY TIMES, pA1
  28. Hanahan D, 2014, LANCET, V383, P558, DOI 10.1016/S0140-6736(13)62226-6
  29. Holmes RS, 2007, SEMIN RADIAT ONCOL, V17, P2, DOI 10.1016/j.semradonc.2006.09.003
  30. Horton S, 2015, CANC DIS CONTROL PRI, V3
  31. Ilbawi AM, 2015, ANN SURG ONCOL, V22, P719, DOI 10.1245/s10434-014-4346-6
  32. International Agency for Research on Cancer, HEL PYL ER START PRE
  33. Kassebaum NJ, 2016, LANCET, V388, P1603
  34. Lee KJ, 2006, INT J CANCER, V118, P2315, DOI 10.1002/ijc.21664
  35. Leung WK, 2008, LANCET ONCOL, V9, P279, DOI 10.1016/S1470-2045(08)70072-X
  36. Levit L, 2013, ADDRESSING CHALLENGE
  37. Lim SS, 2016, LANCET, V388, P1813, DOI 10.1016/S0140-6736(16)31467-2
  38. Lin JS, 2016, JAMA-J AM MED ASSOC, V315, P2576, DOI 10.1001/jama.2016.3332
  39. Lomas A, 2012, BRIT J DERMATOL, V166, P1069, DOI 10.1111/j.1365-2133.2012.10830.x
  40. Loomis D, 2016, LANCET ONCOL, V17, P877, DOI 10.1016/S1470-2045(16)30239-X
  41. Lowy DR, 2016, NEW ENGL J MED, V374, P1901, DOI 10.1056/NEJMp1600894
  42. Mikkelsen L, 2015, LANCET, V386, P1395, DOI 10.1016/S0140-6736(15)60171-4
  43. Miyamoto A, 2007, PREV MED, V44, P12, DOI 10.1016/j.ypmed.2006.07.016
  44. Mizoue T, 2003, INT J CANCER, V106, P103, DOI 10.1002/ijc.11183
  45. Murray CJL, 2013, NEW ENGL J MED, V369, P448, DOI 10.1056/NEJMra1201534
  46. Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
  47. Pera M, 2005, J SURG ONCOL, V92, P151, DOI 10.1002/jso.20357
  48. Peto J, 2004, LANCET, V364, P249, DOI 10.1016/S0140-6736(04)16674-9
  49. Petrick JL, 2016, INT J CANCER, V139, P1534, DOI 10.1002/ijc.30211
  50. Plummer M, 2016, LANCET GLOB HEALTH, V4, pE609, DOI 10.1016/S2214-109X(16)30143-7
  51. Qu CF, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001774
  52. Ryerson AB, 2016, CANCER-AM CANCER SOC, V122, P1312, DOI 10.1002/cncr.29936
  53. Siripongpreeda B, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0526-0
  54. Stefan DC, 2015, J GLOBAL ONCOLOGY, V1, P30, DOI 10.1200/JGO.2015.000406
  55. Steffen A, 2015, INT J CANCER, V137, P646, DOI 10.1002/ijc.29432
  56. Stevens GA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002056
  57. Stringhini S, 2012, AM J EPIDEMIOL, V175, P1275, DOI 10.1093/aje/kwr461
  58. Stringhini S, 2010, JAMA-J AM MED ASSOC, V303, P1159, DOI 10.1001/jama.2010.297
  59. Tsu V, 2016, NEW ENGL J MED, V374, P2509, DOI 10.1056/NEJMp1604113
  60. UN, SUST DEV GOALS
  61. United Nations, 2011 HIGH LEV M PREV
  62. Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2
  63. Vos T, 2016, LANCET, V388, P1545
  64. Wang HD, 2016, LANCET, V388, P1459
  65. World Health Organization, 2016, GLOB HLTH SECT STRAT
  66. World Health Organization, GLOB ACT PLAN PREV C
  67. Wolk A., 2016, J INTERN MED, DOI [10.1111/joim.12543, DOI 10.1111/J0IM.12543]
  68. Yang P, 2009, EUR J CANCER, V45, P2867, DOI 10.1016/j.ejca.2009.04.019
  69. Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - ODS/03